R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
Exp Oncol. 2020 Sep;42(3):192-196. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-3.14981.
Taking into account differences in the bioenergetics between malignant and normal cells a search of antitumor drugs among the modifiers of tumor metabolism has a reasonable excuse. Earlier it was found that the cytotoxic/cytostatic action of sodium dichloroacetate (DCA) against Lewis lung carcinoma (LLC) cells in vitro was enhanced in the case of its combination with metformin (MTF).
To study the antitumor action of DCA in combination with MTF against LLC in vivo.
LLC/R9, a low metastatic variant of LLC cells, was used. LLC/R9 bearing mice were treated with MTF (at a total dose 0.15 g/kg b.w.) alone or in combination with DCA (at a total dose of 0.75 g/kg b.w.). LLC/R9 growth kinetics and the primary tumor growth and metastasis indices on the 23 day after tumor cell inoculation were evaluated by routine procedures. The state of the electron transport chain of mitochondria in tumor cells was studied using electron paramagnetic resonance. The content of lactate and glucose in blood plasma from mice was measured by enzymatic methods using biochemical analyzer. The number of tumor-associated macrophages (TAMs) and their distribution by M1/M2 phenotype were estimated by flow cytometry using antibodies against CD68 and CD206.
In LLC/R9-bearing mice treated with DCA in combination with MTF, tumor growth and metastasis indices, as well as circulating glucose and lactate levels were not significantly different from those in the control group. The level of nitrosylation of non-heme and heme proteins and the content of iron-sulfur centers in the mitochondria of tumor cells in LLC/R9-bearing mice administered with DCA in combination with MTF did not also differ from the corresponding indices in control. Instead, in tumors treated with MTF alone and in combination with DCA the total CD68 TAMs count was almost 27% (p < 0.05) and 43% lower (p < 0.05) correspondingly than that in control, but this decrease was not accompanied by redistribution of CD68/CD206+ and CD68/D206- subsets.
DCA in combination with MTF, at least in doses applied, did not affect LLC/R9 growth and metastasis in vivo. The complete absence of an antitumor effect of DCA in combination with MTF was simultaneously associated with the absence of significant changes in the functional state of electron transport chain of mitochondria in tumor cells, circulating glucose and lactate levels, and the decrease of the TAMs amount in tumors. It suggests that the antitumor activity of DCA and MTF could be determined by both their local effects within a tumor and their multiple systemic impacts.
考虑到恶性细胞和正常细胞之间生物能量的差异,在肿瘤代谢调节剂中寻找抗肿瘤药物是有合理理由的。早些时候发现,二氯乙酸钠(DCA)对体外Lewis 肺癌(LLC)细胞的细胞毒性/细胞抑制作用在与二甲双胍(MTF)联合使用时增强。
研究 DCA 与 MTF 联合对 LLC 体内的抗肿瘤作用。
使用 LLC/R9,LLC 细胞的低转移变体。用 MTF(总剂量 0.15g/kg b.w.)单独或与 DCA(总剂量 0.75g/kg b.w.)联合治疗 LLC/R9 荷瘤小鼠。在肿瘤细胞接种后第 23 天,通过常规程序评估 LLC/R9 的生长动力学、原发性肿瘤生长和转移指数。使用电子顺磁共振研究肿瘤细胞线粒体电子传递链的状态。使用生化分析仪通过酶法测量小鼠血浆中乳酸盐和葡萄糖的含量。使用针对 CD68 和 CD206 的抗体通过流式细胞术估计肿瘤相关巨噬细胞(TAMs)的数量及其 M1/M2 表型的分布。
在接受 DCA 联合 MTF 治疗的 LLC/R9 荷瘤小鼠中,肿瘤生长和转移指数以及循环葡萄糖和乳酸水平与对照组无显著差异。接受 DCA 联合 MTF 治疗的 LLC/R9 荷瘤小鼠肿瘤细胞中非血红素和血红素蛋白的硝化水平以及线粒体中铁硫中心的含量也与对照组的相应指数无差异。相反,单独用 MTF 治疗和联合用 DCA 治疗的肿瘤中,总 CD68 TAMs 计数分别比对照组低 27%(p<0.05)和 43%(p<0.05),但这种减少没有伴随着 CD68/CD206+和 CD68/CD206-亚群的重新分布。
至少在应用剂量下,DCA 联合 MTF 不影响 LLC/R9 在体内的生长和转移。DCA 联合 MTF 完全没有抗肿瘤作用,同时与肿瘤细胞线粒体电子传递链功能状态、循环葡萄糖和乳酸水平以及肿瘤中 TAMs 数量的减少无显著变化有关。这表明 DCA 和 MTF 的抗肿瘤活性可能取决于它们在肿瘤内的局部作用及其对多个系统的影响。